Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change

Program Description

Multiple myeloma (MM) treatment can be complex and burdensome for patients. This program equips oncology pharmacists to combat disparities in MM care, a critical issue as factors like race, ethnicity, and socioeconomic status can limit access to optimal treatment, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. Expert faculty will lead participants in a discussion on evolving data for MM therapies, understanding disparities in cancer care, and pharmacist-led strategies to improve care delivery within the MM treatment landscape. Key areas of personalized treatment planning, cultural competency, and collaboration will be addressed, ensuring that pharmacists within oncology care teams can support initiatives that provide equitable access to optimal MM treatment, ultimately improving patient outcomes and reducing treatment disparities in MM.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: August 28, 2024
Expiration date: August 28, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the safety and efficacy of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma
• Explain the impact of various factors, such as race, ethnicity, socioeconomic status, and geography, on disparities in the treatment of multiple myeloma
• Identify opportunities for pharmacists to actively engage in initiatives aimed at reducing treatment disparities in multiple myeloma

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-245-H01-P. The activity is available for CE credit through August 28, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Britny Brown, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Grant/Research Support: Bayer

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms